Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - methylprednisolone aceponate - ointment - 0.1%w/w percent weight/weight - methylprednisolone aceponate

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - methylprednisolone aceponate - cream - 0.1%w/w percent weight/weight - methylprednisolone aceponate

Ireland - English - HPRA (Health Products Regulatory Authority)

leo pharma a/s - methylprednisolone aceponate - ointment - 0.1 percent weight/weight - methylprednisolone aceponate

Ireland - English - HPRA (Health Products Regulatory Authority)

leo pharma a/s - methylprednisolone aceponate - cream - 0.1 percent weight/weight - methylprednisolone aceponate

Israel - English - Ministry of Health

genmedix , israel - methylprednisolone as hemisuccinate - lyophilized powder for injection - methylprednisolone as hemisuccinate 500 mg - methylprednisolone - methylprednisolone mylan is indicated to treat any condition in which iv corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation

New Zealand - English - Medsafe (Medicines Safety Authority)

leo pharma limited - methylprednisolone aceponate 0.1%{relative} - topical cream - 0.1 % - active: methylprednisolone aceponate 0.1%{relative} excipient: benzyl alcohol butylated hydroxytoluene cetostearyl alcohol decyl oleate glycerol glyceryl monostearate hard fat macrogol stearate 2000 purified water sodium edetate softisan 378 - atopic dermatitis (endogenous eczema, neurodermatitis), contact eczema, degenerative, dyshidrotic, vulgar eczema, eczema in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

leo pharma limited - methylprednisolone aceponate 0.1%{relative} - topical ointment - 0.1 % - active: methylprednisolone aceponate 0.1%{relative} excipient: dehymuls e liquid paraffin purified water white beeswax white soft paraffin - atopic dermatitis (endogenous eczema, neurodermatitis), contact eczema, degenerative, dyshidrotic, vulgar eczema, eczema in children.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 4 mg - methylprednisolone tablets are indicated in the following conditions: - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected ca

United States - English - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 4 mg - methylprednisolone tablets are indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematos

United States - English - NLM (National Library of Medicine)

unit dose services - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 4 mg - methylprednisolone tablets are indicated in the following conditions: 1.endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2.rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis 3.collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus